Oncology

Latest News

Within 5 years, the risk of SCC in particular was heightened among patients with MMP. | Image credit: wavebreak3 - stock.adobe.com
Rare Autoimmune Disorder Linked With Increased Risk of Certain Skin Cancers

April 21st 2025

The risk of some skin cancers, including squamous cell carcinoma, basal cell carcinoma, and non-melanoma skin cancer, was particularly heightened among patients with severe mucous membrane pemphigoid.

AI technology | Image: Adobe Stock
Tech Updates: McKesson Launches Precision Oncology Consortium; Financing for RISA Labs PA Platform

April 17th 2025

IVBM Atlanta | Image credit: AJMC
Making Novel Cancer Therapies Available Requires Choices Because Resources Are Limited

April 14th 2025

Businessman shows medical network wooden block for health, medicine, insurance, healthcare, care, concept. Medical technology services to solve public - ภัทรชัย รัตนชัยวงค์ - stock.adobe.com.jpeg
NCCN Data Find Racial, Socioeconomic Disparities in Quality of Care for Metastatic Pancreatic Cancer

April 9th 2025

AJMC
Comparing Breast Cancer Treatment Outcomes Between Fee-for-Service and Medicare Advantage

April 4th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Site Logo
June 14th 2016

A Smarter Screening Strategy for Prostate Cancer Can Predict Mortality

Surabhi Dangi-Garimella, PhD
A collaborative effort by urologists and public health specialists from various healthcare systems around the country has found that PSA levels measured in midlife (45 to 59 years of age) are a strong predictor of future lethal prostate cancer.
Site Logo
June 14th 2016

Adjuvant Chemotherapy Can Improve Survival in Early Stage NSCLC

Surabhi Dangi-Garimella, PhD
A new study, published in the Journal of Thoracic Oncology, has found that chemotherapy administered in patients with stage I disease, following a complete resection, can have a significant impact on their median 5-year overall survival.
Site Logo
June 14th 2016

What We're Reading: CMS May Require Medicare Hospitals Follow New Antibiotic Controls

AJMC Staff
What we're reading, June 14, 2016: CMS has proposed requiring Medicare hospitals follow new antibiotic controls; New York poised to expand access to breast cancer screening; and clinical trials are seeing more success.
Dr Steve Miller Weighs Pros and Cons of Medicare Part B Proposal
June 14th 2016

Dr Steve Miller Weighs Pros and Cons of Medicare Part B Proposal

The new Medicare Part B proposal from CMS has been controversial, and Steve Miller, MD, senior vice president and chief medical officer of Express Scripts, understands both sides of the argument. While he appreciates CMS' dedication to innovation, the demonstration may drive up payer costs.
Site Logo
June 13th 2016

What We're Reading: WHO Recommends Delaying Pregnancy in Zika-Infected Areas

AJMC Staff
What we're reading, June 13, 2016: the World Health Organization is recommending women in Zika-infected areas delay pregnancy; one FDA regulator feels too many drug makers are chasing the same treatments in cancer care; and risky behaviors among American teenagers are down.
Site Logo
June 13th 2016

Survey Finds Family Physicians Divided on Recommending LDCT Screening

Surabhi Dangi-Garimella, PhD
A survey conducted among members of the South Carolina Academy of Family Physicians found that although most family physicians reported that they discussed low-dose computed tomography screening (LDCT) with their patients, referrals were low
This Week in Managed Care: June 11, 2016
June 11th 2016

This Week in Managed Care: June 11, 2016

This week in managed care, the top stories included discussions on biomarkers and financial toxicity at the annual meeting of the American Society of Clinical Oncology, and a preview of the 76th Scientific Sessions of the American Diabetes Association.
Site Logo
June 10th 2016

Systemic Lupus Erythematosus a Risk Factor for Cervical Cancer

AJMC Staff
Results presented at the European League Against Rheumatism Annual Congress have confirmed that Systemic Lupus Erythematosus can increase the risk of developing cervical cancer in women.
Site Logo
June 10th 2016

NICE Not Alone in Pushback on Cancer Drug Prices

Surabhi Dangi-Garimella, PhD
The Colombian government is forcing pharmaceutical giant Novartis to lower prices of its leukemia medicine, imatinib (Gleevec).
Site Logo
June 9th 2016

Lack of Palliative, Hospice Care Seen Among Veterans Dying of Cancer

Jackie Syrop
Only half of US veterans who died from cancer received palliative care, while the use of hospice depended upon the care environment. Overall, there was a gap between the percentage of patients who received palliative care and recommended use.
Site Logo
June 9th 2016

Cancer Drug Prices Follow a Sharp Upward Trajectory Post Launch

Surabhi Dangi-Garimella, PhD
A group in Israel presented a study that evaluated the price trend of 30 anticancer agents following their launch, and found that prices may increase by as much as 44% even after adjusting for inflation.
Site Logo
June 9th 2016

So Many Metrics, Yet So Little Known About Quality and Value in Cancer Care

Joseph Alvarnas, MD
As cancer care stakeholders move through processes of creating, deploying, and reporting quality metrics, it is important to remember that these measures alone are not sufficient to bring better care to patients.
Site Logo
June 9th 2016

German-Australian AML Study Group Identifies 11 Classes of AML

Surabhi Dangi-Garimella, PhD
The German-Australian AML Study Group, one of the largest global groups evaluating treatments for acute myeloid leukemia (AML), has published results in the New England Journal of Medicine that now classifies AML into 11 classes based on the harbored genetic mutations.
Site Logo
June 8th 2016

ASCO Study Finds Daratumumab Economical Over Other Novel MM Agents

Surabhi Dangi-Garimella, PhD
A poster presented at the annual meeting of the American Society of Clinical Oncology (ASCO) found that the cost per median month of survival for daratumumab was lower compared with 2 other novel treatments in multiple myeloma.
Site Logo
June 8th 2016

A $67 Million Fine for False Claims on Erlotinib

Surabhi Dangi-Garimella, PhD
The Department of Justice has announced that Genentech and OSI Pharmaceuticals “will pay $67 million to resolve False Claim Act allegations that they made misleading statements about the effectiveness of the drug Tarceva to treat non-small cell lung cancer.”
Site Logo
June 7th 2016

Aggressive Cancer Care Widely Used Among Patients at the End of Life

Cate Douglass
Many patients 65 years or younger are still receiving aggressive cancer treatment in their final months of life despite Choosing Wisely recommendations encouraging symptom-directed palliative care.
Site Logo
June 7th 2016

The Value of a 21-Gene Test in Early-Stage Breast Cancer

Surabhi Dangi-Garimella, PhD
Can the Oncotype DX Breast Cancer Assay impact recommendation and receipt of chemotherapy in early stage breast cancer? Does the test also improve patient experience? These were some of the questions asked by researchers at the University of Michigan, and the results presented during the annual meeting of the American Society of Clinical Oncology.
Site Logo
June 7th 2016

What We're Reading: Opioid Restrictions Hurt Those Who Need the Drugs Most

AJMC Staff
What we're reading, June 7, 2016: opioid restrictions disproportionately affect older patients with chronic pain; Genentech and OSI Pharmaceuticals settle Tarceva lawsuit; and trouble raising Zika virus funds.
Site Logo
June 7th 2016

ASCO's TAPUR Study Continues to Grow

Cate Douglass
The American Society of Clinical Oncology’s first-ever clinical trial is growing with the addition of its seventh and eighth pharmaceutical companies, Bayer and Merck, and 30 additional trial participants.
Dr Michael Kolodziej: Insurers May Never Use Value Frameworks
June 6th 2016

Dr Michael Kolodziej: Insurers May Never Use Value Frameworks

With value frameworks still in their infancy, Michael Kolodziej, MD, national medical director for oncology strategy at Aetna, doesn't see how his company can use them just yet. In fact, these frameworks may never be used by insurers, but only for shared decision making between the patient and provider.
Site Logo
June 6th 2016

Clinical Interpretation of the ASCO Recommendations on Quality and Value

Surabhi Dangi-Garimella, PhD
A session at the ongoing annual meeting of the American Society of Clinical Oncology (ASCO) provided an overview of ASCO's recently updated value framework and their quality program, the Quality Oncology Practice Initiative.
Site Logo
June 6th 2016

ASCO Results: Diabetes Drug Shows Promise in Cancer Treatment, Prevention

Mary Caffrey
The first study sheds light on the complex interaction between underlying metabolic risk and breast cancer.
Site Logo
June 6th 2016

What We're Reading: Biden Will Announce Launch of Open-Access Cancer Database

AJMC Staff
What we're reading, June 6, 2016: Vice President Joe Biden will announce the launch of an open-access cancer research database, and a new bill in Congress would allow companies to repurpose existing drugs for rare diseases.
Site Logo
June 6th 2016

Zeroing in on Predictive Biomarkers for Cancer Immunotherapy

Surabhi Dangi-Garimella, PhD
While several clinical trials have tried to identify a programmed death-1 or programmed death ligand-1 expression—dependent response, it’s been an uphill task. During one of the sessions at the annual meeting of the American Society of Clinical Oncology, researchers were tasked with sharing their data on any breakthroughs or leads with biomarker-based treatment.
Patricia Goldsmith Describes the Financial Challenges Oncology Patients Face
June 5th 2016

Patricia Goldsmith Describes the Financial Challenges Oncology Patients Face

CancerCare provides oncology patients with many services that offer both educational and financial support as well as any help the patient may need with his or her family, such as child care and housekeeping needs. However, Patricia Goldsmith, CEO of CancerCare, explained that there are many financial challenges, including transportation and high out-of-pocket costs, that oncology patients continue to face.
Dr John Fox: The Oncology Medical Home Model Can Decrease Costs
June 5th 2016

Dr John Fox: The Oncology Medical Home Model Can Decrease Costs

The key to driving down costs, or at the very least making costs more predictable, is integrating pathways into the Oncology Care Model program, said John L. Fox, MD, MS, associate vice president of medical affairs at Priority Health.
Site Logo
June 5th 2016

Understanding and Mitigating the Financial Burden of Cancer Patients

Surabhi Dangi-Garimella, PhD
Drug costs are a significant contributor to rising healthcare costs, along with the cost of healthcare services. How can providers and patients work together to find a solution to this problem?
Site Logo
June 5th 2016

The Promise of CAR-T Cells in Leukemia and Lymphoma

During a session on the second day of the annual meeting of the American Society of Clinical Oncology, experts discussed treating patients with chimeric antigen receptor T cells (CAR-T cells).
Dr Bhuvana Sagar on Using Data Generated From Value Frameworks
June 4th 2016

Dr Bhuvana Sagar on Using Data Generated From Value Frameworks

Though Cigna’s reimbursement medical home model is still in its very early stages, Bhuvana Sagar, MD, national medical director of Cigna Healthcare, explained that discussing value in healthcare and getting back to smarter spending as well as better outcomes for patients should be the focus of all industry stakeholders.
Dr Lucio Gordan Names His Most Exciting Development in Oncology in the Last Year
June 4th 2016

Dr Lucio Gordan Names His Most Exciting Development in Oncology in the Last Year

New immunotherapies and biologics that are changing the landscape when it comes to treating patients are the most exciting development in oncology in the last year, according to Lucio Gordan, MD, of Florida Cancer Specialists.
<1
...
9899100101102103104105106
...
184>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo